Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome

Neurodevelopmental disorders such as fragile X syndrome (FXS) result in lifelong cognitive and behavioural deficits and represent a major public health burden. FXS is the most frequent monogenic form of intellectual disability and autism, and the underlying pathophysiology linked to its causal gene,...

Full description

Bibliographic Details
Main Authors: Berry-Kravis, Elizabeth M., Lindemann, Lothar, Jønch, Aia E., Apostol, George, Bear, Mark, Carpenter, Randall L, Crawley, Jacqueline N., Curie, Aurore, Des Portes, Vincent, Hossain, Farah, Gasparini, Fabrizio, Gomez-Mancilla, Baltazar, Hessl, David, Loth, Eva, Scharf, Sebastian H., Wang, Paul P., Von Raison, Florian, Hagerman, Randi, Spooren, Will, Jacquemont, Sébastien
Other Authors: Picower Institute for Learning and Memory
Format: Article
Language:English
Published: Springer Science and Business Media LLC 2020
Online Access:https://hdl.handle.net/1721.1/126440

Internet

https://hdl.handle.net/1721.1/126440

Similar Items